Peripartum cardiomyopathy (PPCM) is a potentially life-threatening condition typically presenting as heart failure with reduced ejection fraction (HFrEF) in the last month of pregnancy or in the months following delivery in women without another known cause of heart failure. This updated position statement summarizes the knowledge about pathophysiological mechanisms, risk factors, clinical presentation, diagnosis and management of PPCM. As shortness of breath, fatigue and leg oedema are common in the peripartum period, a high index of suspicion is required to not miss the diagnosis. Measurement of natriuretic peptides, electrocardiography and echocardiography are recommended to promptly diagnose or exclude heart failure/PPCM. Important differential diagnoses include pulmonary embolism, myocardial infarction, hypertensive heart disease during pregnancy, and pre-existing heart disease. A genetic contribution is present in up to 20% of PPCM, in particular titin truncating variant. PPCM is associated with high morbidity and mortality, but also with a high probability of partial and often full recovery. Use of guideline-directed pharmacological therapy for HFrEF is recommended in all patients
Introduction
The aetiology of cardiomyopathies occurring de novo in association with pregnancy is diverse. Cardiomyopathies are not very common diseases, but may cause severe complications, making a substantial contribution to maternal morbidity and mortality during pregnancy, in the immediate peripartum period, and up to months later. 1 Peripartum cardiomyopathy (PPCM) has to be differentiated from other causes of heart failure. The ongoing international PPCM registry in the EURObservational Research Programme (EORP) has recruited over 750 patients and will be the largest dataset to provide important novel information on PPCM. 2, 3 It is unclear in what percentage PPCM persists to chronic, stable heart failure as patients with non-specific symptoms around pregnancy may remain undiagnosed and are only identified months or years later. How often heart failure in younger women is caused by PPCM will not be determined until there is a large pregnancy cohort study which includes monitoring of cardiac function.
Heart failure due to PPCM provides a challenge for treating physicians as PPCM presentation may vary from subtle signs and symptoms to severe acute heart failure, pulmonary oedema and/or cardiogenic shock. 4, 5 Moreover therapeutic interventions need always to consider both the health of the mother and the foetus or baby. While evidence-based data from randomized clinical trials are scarce, in this position statement we summarize the current knowledge about pathophysiology and clinical best practice in the management of PPCM patients.
Definition and epidemiology
In 2010, the Study Group on peripartum cardiomyopathy of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) defined PPCM as an idiopathic cardiomyopathy occurring towards the end of pregnancy or in the months following delivery, abortion or miscarriage, without other causes for heart failure, and with a left ventricular (LV) ejection fraction (EF) < 45% 5 (see Box). Given the fact that there are some patients with typical features of PPCM and a clear impairment of LVEF, also patients with an EF value between 45% and 50% may occasionally be diagnosed with PPCM. Since no specific test to confirm PPCM exists, it remains a diagnosis of exclusion, and differential diagnoses need to be considered. In particular, aggravation of a pre-existing heart disease by pregnancy-mediated haemodynamic changes should be . differentiated from PPCM. Cases of acute Takotsubo syndrome during the final trimester or following emergency delivery have been reported, and these require careful assessment to differentiate from PPCM. 6, 7 Definition of peripartum cardiomyopathy 1. Heart failure secondary to left ventricular systolic dysfuntion with a LVEF < 45% 2. Occurrence towards the end of pregnancy or in the months following delivery (mostly in the month following delivery) 3. No other identifiable cause of heart failure The incidence of PPCM differs widely depending on the ethnic/racial and regional background of women. Africans and African Americans are at a higher risk for developing PPCM, with an estimated incidence of 1:100 pregnancies in Nigeria and 1:299 in Haiti whereas incidences in Caucasian populations range from 1:1500 pregnancies in Germany to 1:10 000 in Denmark. 5,8 -13 In a large US cohort of well-phenotyped patients, African American women were diagnosed with PPCM at a younger age and later in the postpartum period, and were more likely to present with a LVEF < 30% compared with non-African American women. 10 In the USA, an increasing incidence was described over the past years. 8 In a Japanese cohort the incidence was as low as 1:20 000, 14 however, these data should be interpreted with caution due to methodological aspects and possible underreporting. In contrast, an analysis that appears more representative of the Asian population was published recently from a nationwide database and estimated the incidence of PPCM in South Korea at 1:1741.
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(predisposition) is thought to be crucial in the pathophysiology of PPCM. 26, 27 Possible factors leading to PPCM include genetic predisposition, low selenium levels, viral infections, stress-activated cytokines, inflammation, autoimmune reaction, pathological response to haemodynamic stress, unbalanced oxidative stress and induction of antiangiogenic factors. 17 -19,23,26,28-32 Particularly, the oxidative stress-mediated cleavage of the hormone prolactin into a smaller antiangiogenic subfragment, 16-kDa prolactin, may drive PPCM by inducing endothelial damage. 29, 33 Release of endothelial microparticles loaded with active compounds such as microRNAs, whose release into the circulation is also induced by 16-kDa prolactin, may subsequently impair cardiomyocyte metabolism and further contribute to the manifestation of PPCM. 13, 27, 29, 33, 34 The link between vascular pregnancy complications (e.g. pre-eclampsia) and PPCM was strengthened by the observation that women with PPCM had high levels of soluble fms-like tyrosine kinase 1 (sFlt-1), a potent vascular endothelial growth factor inhibitor, which has been implicated in the pathogenesis of pre-eclampsia, suggesting an overlap between these conditions. Indeed, pro-angiogenic therapies could rescue the PPCM phenotype in experimental models. In conclusion, PPCM is a complex disease with a quite heterogeneous and incompletely understood pathophysiology involving angiogenic, metabolic, hormonal and oxidative stress factors.
Genetic aspects
Genetically transmitted dilated cardiomyopathy (DCM) may manifest during early adulthood, and is sometimes difficult to distinguish from PPCM. 17, 19, 35, 36 Indeed, recent observations support the notion that around 15-20% of patients with peripartum heart failure carry mutations known to induce cardiomyopathies, i.e. in genes like titin, beta-myosin heavy chain, myosin-binding protein C (MYBPC3), lamin A/C or sodium voltage-gated channel alpha subunit 5 (SCN5A). 17, 19, 35, 36 One theory is that in gene-positive, phenotype-negative women without clinical symptoms prior to pregnancy, the physiological stress of pregnancy and delivery may unmask concealed DCM. 37 Further investigation is needed regarding mutations or polymorphisms in genes regulating metabolism, oxidative stress response, angiogenesis and the immune system as well as the higher frequency of PPCM in women of African ancestry. 10, 13, 27, 38 Genetic testing may be considered in PPCM, in particular in those patients with a positive familial history.
Clinical presentation and (differential) diagnosis
While the majority of patients with PPCM present in the early postpartum period, there should also be a high index of suspicion towards the end of pregnancy. 3 The differential diagnoses differ according to stage of presentation -pre-vs. postpartum. An important differential diagnosis in patients presenting with acute heart failure at the end of pregnancy or directly post-delivery is severe (pre-)eclampsia leading to pulmonary oedema mainly due to diastolic dysfunction. In a South African cohort comparing hypertensive heart failure of pregnancy (HHFP) and PPCM, 39 PPCM was more often associated with twin pregnancy, smoking, cardiomegaly with lower LVEF, left atrial hypertrophy, QRS abnormalities, T-wave inversion and atrial fibrillation. By contrast, HHFP patients were more likely to have a family history of hypertension, hypertension and pre-eclampsia in a previous pregnancy, tachycardia at presentation, and LV hypertrophy. Mortality was 17% in PPCM compared to 0% among HHFP. Those data suggest significant differences in presentation and outcome of those two conditions that impact the long-term management, prognosis and advice about subsequent pregnancy.
In case of cardiogenic shock, pregnancy-associated myocardial infarction, pulmonary embolism and amniotic fluid embolism should be considered. 4 In the post-delivery situation, PPCM often presents with slowly developing heart failure with non-specific symptoms like shortness of breath, fatigue, chest pain, cough and abdominal discomfort leading to late diagnosis. 40 PPCM should be suspected in all women with a delayed return to the pre-pregnancy state. Table 2 summarizes the diagnostic tests that are recommended for the diagnosis of PPCM at initial diagnosis and at follow-up visits.
In general, PPCM has to be differentiated from other causes of heart failure such as (pre-existing) DCM, adult congenital heart disease, toxic cardiomyopathy after e.g. chemotherapy, and Takotsubo syndrome. 5, 7, 13, 27 Particularly after a very stressful labour or emergency due to foetal complications, high maternal catecholamine levels as well as uterotonic or tocolytic drugs with catecholaminergic properties may trigger Takotsubo syndrome. 7 In a recent analysis of the worldwide EORP PPCM registry, characteristics and risk factors of PPCM patients with different ethnicities (including Asians) were reported. 3 Despite the huge differences in ethnic and socio-economic backgrounds among regions of the world, the baseline characteristics and mode of presentation of PPCM patients were remarkably similar. Figure 1 summarizes the diagnostic pathway in patients with suspected PPCM including electrocardiogram (ECG), determination of natriuretic peptides, X-ray and echocardiography (according to local availability not all four have to be performed in all patients). 
Electrocardiogram
An ECG should be performed in all patients with suspected PPCM because it is safe, inexpensive and may help distinguish PPCM from other causes of symptoms. Although there is no specific ECG pattern for PPCM, at initial evaluation, the ECG is rarely normal and repolarization abnormalities are common. 41 -43 Left bundle branch block may be an indirect sign for cardiomyopathy a Bromocriptine may be considered in PPCM patients (class IIb recommendation) and should be accompanied by at least prophylactic anticoagulation. and structural heart disease should be ruled out in these women. 44 A recent study identified a long QTc interval at baseline which was found in almost 50% of the patients, and tachycardia as predictors of poor outcome in PPCM. 45 
Biomarkers
Concerning diagnostic properties of natriuretic peptides, one should keep in mind that B-type natriuretic peptide (BNP)/N-terminal proBNP (NT-proBNP) levels are not or only slightly elevated in normal pregnancy. 46 By contrast, patients with acute PPCM have consistently elevated plasma concentrations of natriuretic peptides, BNP or NT-proBNP. 5, 11 The most important role of natriuretic peptides is to rule out heart failure (with a threshold < 100 pg/mL for BNP and < 300 pg/mL for NT-proBNP can be ruled out with high probability), and they should not be used solely to establish the diagnosis of PPCM. Although one study demonstrated plasma BNP levels > 1860 pg/mL as an independent factor for persistent LV dysfunction, prognostic properties of natriuretic peptides remain uncertain. 47, 48 Serum troponin concentrations measured at baseline may predict persistent LV dysfunction after 6 months. 49 More specific biomarkers would be helpful to allow a faster and more reliable diagnosis of PPCM, but these are yet to be adequately defined. Candidates involve 16 kDa-prolactin, interferon-gamma, asymmetric dimethylarginine (ADMA) and microRNA-146a. 11, 29, 32 There is controversy on the impact of imbalanced angiogenesis. Recently, high placenta growth factor (PlGF) and/or low sFlt-1/PlGF were suggested to be useful to diagnose PPCM. More research in this field is needed before any recommendations can be made.
Cardiac imaging
Echocardiography is indicated as soon as possible in all cases of suspected PPCM to confirm the diagnosis, assess concomitant or pre-existing cardiac disease, exclude complications of PPCM (e.g. LV thrombus) and obtain prognostic information (for example LVEF and pulmonary hypertension). After stabilization, magnetic resonance imaging may provide a more accurate evaluation of cardiac structure and function, and can sometimes be helpful if there is high suspicion for another diagnosis such as arrhythmogenic right ventricular cardiomyopathy and myocarditis. The incremental value of cardiac magnetic resonance imaging in addition to echocardiography is uncertain. Administration of gadolinium to assess late enhancement should be avoided until after delivery due to the increased risk of stillbirth, neonatal death, and rheumatological, inflammatory, or infiltrative skin conditions.
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Endomyocardial biopsy
Endomyocardial biopsy adds limited diagnostic or prognostic information in PPCM. It may be used to exclude acute myocarditis after delivery, reveal significant viral presence, and exclude rare autoimmune myocarditis, storage or metabolic disease. 52 Whether or not myocarditis can be a mechanism of PPCM or whether myocarditis is a distinct entity is unclear. Myocarditis has been identified occasionally in patients thought to have PPCM. 53 Routine endomyocardial biopsy is not recommended in patients with suspected PPCM.
Management Acute heart failure
In cases when PPCM presents with acute, decompensated heart failure (see Figure 2 , clinical scenario acute heart failure/cardiogenic shock), the guidelines for the management of acute heart failure apply. 54, 55 For rapid diagnosis and decision making in all pregnant women with acute heart failure, a pre-specified management algorithm and the establishment of a multidisciplinary team is crucial. 4, 56, 57 Multidisciplinary care includes cardiologists, intensivists, obstetricians, neonatologists, anaesthetists and cardiac surgeons (see Figure 1 in ref. 4) . Timely diagnosis and treatment are crucial. A recommended treatment algorithm for patients with acute PPCM is given in Figure 2 in ref. 4 . Clearly, the initial treatment of patients with severe forms of acute PPCM is different to those of stable patients (Figure 2) .
If a patient is in cardiogenic shock/dependent on inotropes, she should be transferred immediately to an advanced heart failure centre where mechanical circulatory support (MCS), ventricular assist devices (VAD), and transplant consult teams are available. 4, 55 Experimental data and a study in PPCM patients indicated that patients with PPCM may be especially sensitive to toxic effects of beta-adrenergic receptor stimulation which should be avoided whenever possible. 25 Norepinephrine is indicated to restore blood pressure, and levosimendan may be considered, however the only (small) randomized clinical trial in PPCM patients . did not show a beneficial effect on outcome. 4, 58 The teratogenic effects of inotropic support and vasopressors in humans are unknown but their use may be necessary. In PPCM patients with severely reduced LV function and/or cardiogenic shock, VAD implantation as bridge to recovery or transplantation can be necessary (2-7% of PPCM patients). 4, 9, 11 It is important to note, however, that a significant proportion of PPCM patients improve or normalize their LV function over the first 6 months after diagnosis, which must be considered when decisions are made. 4 Short-term assist devices, e.g. microaxial pump, Centrimag or venoarterial extracorporeal membrane oxygenation (ECMO), may be required. 59 Long-term assist devices with left VAD or biventricular VAD can be implanted and some have been explanted after recovery. 60, 61 Due to the toxic effects of beta-adrenergic agonists specifically in PPCM, MCS may be considered with a lower threshold than in other patients with inotrope-dependent cardiogenic shock. 25 
Heart transplantation in peripartum cardiomyopathy
Early cardiac transplantation should be reserved for patients with refractory severe heart failure where MCS is not possible or not desirable for individual reasons, mainly for cases with biventricular failure or severe initial right ventricular dysfunction. 62 Patients with PPCM appear to have higher rates of graft failure and death after heart transplantation, which may be partly explained by higher allosensitization, higher pre-transplant acuity, and increased rejection. 63 As late recovery beyond 6-12 months is possible 64 and outcomes with heart transplantation in PPCM are worse than in other causes of heart failure, delaying heart transplantation as long as possible is desirable.
Stabilized/chronic heart failure
For treatment of stabilized/chronic heart failure, the pregnancy status of the patient is important. Women who present with PPCM during pregnancy require joint cardiac and obstetric care. 4, 57 Possible adverse effects on the foetus must be considered when prescribing drugs. Drugs for heart failure that can and cannot be used during pregnancy are described in Table 3 . During pregnancy, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), angiotensin receptor-neprilysin inhibitors (ARNI), ivabradine and mineralocorticoid receptor antagonists (MRAs) are contraindicated because of concerns of teratogenicity and foetotoxicity. 13, 56 Hydralazine, e.g. 25 mg every 6 h, and nitrates, e.g. isosorbide dinitrate 20 mg once daily with up-titration as tolerated, can be used during pregnancy instead of ACE inhibitors/ARBs for afterload reduction. Beta-blocker treatment is indicated for all patients with PPCM whether or not the patient is pregnant or after delivery. These drugs should only be started in patients who are euvolaemic and clinically stable. Diuretics should be used if patients have symptoms or signs of congestion whether or not they are pregnant, despite concerns about placental blood flow. Post-delivery whether or not a woman is breastfeeding should be established when considering the choice of drug therapy for heart failure. For those who are breastfeeding, the drugs that can and cannot be used are also described in Table 3 ; it should be acknowledged that there are limited data to guide these recommendations. The risks of drugs during lactation cannot be described clearly but our expert-based recommendations attempt to balance the likely pros of therapy for heart failure against potential cons. Many drugs, including ACE inhibitors, beta-blockers and MRAs, pass into human breast milk but this is often at clinically insignificant levels. A summary of previously published guidance in national and international guidelines (including from the World Health Organization) is included in the online supplementary Table S1 . These prior guidelines illustrate a lack of definitive data as they are frequently discordant both with each other and sometimes even within the same document.
For those not breastfeeding, heart failure should be treated according to guidelines on acute and chronic heart failure including ACE inhibition, beta-blockade and MRAs, and then replacing ACE inhibitors and ARBs with ARNI 13,54 ( Table 4) . As high resting heart rate is a predictor of adverse outcome, treatment with ivabradine might be useful in PPCM patients with high heart rate in sinus rhythm on top of beta-blockade. 65, 66 All patients should remain on a combined drug regimen for heart failure until they experience complete myocardial recovery and for at least 12-24 months after full recovery of LV function.
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Following complete recovery, how long medical therapy should continue is unknown. Many clinicians recommend that all patients with PPCM remain on long-term therapy to avoid the potential decline in cardiac function which is a risk on stopping pharmacological therapy for heart failure. 67 Others believe that drugs can be gradually withdrawn under careful surveillance with serial cardiac imaging and biomarker measurement. A full discussion between patient, family and clinicians is necessary where the pros and cons of stopping or continuing therapy are carefully considered. Data to guide these decisions are limited. In a small cohort with recovered LV function post-PPCM who stopped their drug therapy, none experienced worsening of LV function; but this is not definitive evidence for the safety of withdrawing drug therapy in patients who have PPCM. 68 In those patients with an identified genetic contribution, indefinite continuation of heart failure therapy is recommended. 69 When a patient wishes to consider a subsequent pregnancy (following a fully informed decision-making process) drug therapy can be withdrawn under close monitoring for around 6 months before embarking on conception and pregnancy.
Pro-coagulant activity is increased during and early after pregnancy. 70 In the context of reduced EF in PPCM, initial treatment with low molecular weight heparin or oral anticoagulation at least in prophylactic dose is recommended because of the high rate of peripheral arterial and venous embolism (7% in the first 30 days after delivery, data from the PPCM worldwide registry). 
Delivery
Vaginal delivery is always preferable if the patient is haemodynamically stable and there are no absolute obstetric indications for caesarean delivery. Close haemodynamic monitoring is required. Epidural analgesia is preferred. Urgent delivery irrespective of gestation duration should be considered in women with advanced heart failure and haemodynamic instability despite optimal heart failure treatment. 4 In these cases, caesarean section is recommended with central neuraxial anaesthesia. To prevent abrupt pressure or volume changes, epidural anaesthesia might be the method of choice but should be carefully titrated, guided by an expert anaesthetic team. 4, 56, 57 If MCS may become necessary, the patient should be delivered by appropriate teams in hospitals capable of providing such care.
Breastfeeding
Breastfeeding in patients with heart failure is controversial. According to the 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy, 56 in patients with severe heart failure preventing lactation may be considered due to the high metabolic demands of lactation and breastfeeding (class IIb recommendation). These guidelines state that stopping lactation enables safe treatment with all established heart failure drugs. Normal growth percentiles and no adverse outcome for infants were observed in a collective of PPCM patients in South Africa where breastfeeding was terminated. 71 However, breastfeeding is tolerated by many women with PPCM with respect to their heart failure status. Additionally, many drugs for heart failure are also not contraindicated in breastfeeding mothers (see above and Table 3 ). Breastfeeding may also confer important benefits to infants and mothers, especially in developing countries. Numerous national and international guidelines, including from the World Health Organization, advise that many heart failure drugs are compatible with breastfeeding if used with caution (see online supplementary Table S1 ). Data on infant safety with breastfeeding is very limited however, and often involves older therapeutic agents and tiny patient numbers. Many drugs, including ACE inhibitors, beta-blockers and MRAs, pass into human breast milk but this is often at clinically insignificant levels (see online supplementary Table S1 ). Most studies often also involve single agents, rather than combinations of drugs. Breastfeeding may also confer important physical and psychological benefits to infants and mothers, especially in developing countries. 72 Decisions on whether to inhibit lactation, terminate breastfeeding or continue breastfeeding with caution should be taken jointly with the patient on a case-by-case basis, taking into consideration both the health of the mother and the risk:benefit ratio of breastfeeding to the infant. Good counselling and shared decision-making are key. Online supplementary Table S1 summarizes the current literature around lactation safety and heart failure drugs and may help guide clinicians, should mothers wish to continue breastfeeding.
Bromocriptine treatment
Based on the above-mentioned pathophysiological pathway of 16kD-prolactin-mediated PPCM, a small (n = 20) prospective Please note that initiation of all heart failure drugs is only possible in patients who do not breastfeed (see also Table 3 and online supplementary Table S1 for a more comprehensive summary of compatibilities with breastfeeding). ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; LV, left ventricular; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association.
randomized pilot study supported the hypothesis that the addition of the prolactin-blocker bromocriptine to standard heart failure therapy has beneficial effects on LVEF and mortality in women with severe acute PPCM. 71 Furthermore, in the German PPCM registry, standard heart failure plus bromocriptine treatment was associated with low mortality. 11 The randomized prospective German bromocriptine study compared short-and long-term bromocriptine treatment in patients with severe PPCM (EF < 35%). 73 Both high and low doses were associated with low mortality (there was no placebo arm). A Canadian study reported a greater LV recovery in PPCM patients treated with bromocriptine. 74 Treatment with bromocriptine may especially be considered in patients with right ventricular involvement. 75 A bromocriptine treatment scheme has been suggested: bromocriptine (2.5 mg once daily) for at least 1 week may be considered in uncomplicated cases, whereas prolonged treatment (2.5 mg twice daily for 2 weeks, then 2.5 mg once daily for another 6 weeks) may be applied in patients with EF < 25%, right ventricular involvement, intensive care treatment, and/or cardiogenic shock (Figure 3) . 76 There is no consensus as to whether or not bromocriptine should be used in PPCM. Some believe that as acute heart failure due to PPCM can have a poor prognosis in some patients and there are no evidence-based drug treatments, bromocriptine should be used.
Data on bromocriptine treatment in PPCM patients with cardiogenic shock are scarce. support. 77 Individualized bromocriptine treatment with dose up-titration until successful prolactin suppression is achieved is a possible therapeutic option in these highly selected cases. 59 The safety profile seems reasonable when at least prophylactic anticoagulation is administered. 59 International variations in the use of bromocriptine are large: in the USA bromocriptine is rarely used 9 whereas in Germany and non-EU countries in the worldwide PPCM registry, treatment with bromocriptine is common. 3 There are no large, randomized, placebo-controlled trials of bromocriptine in PPCM. A small (n = 60) bromocriptine vs. placebo trial is underway in Canada. Considerably larger, international placebo-controlled trials would be necessary to establish firm proof of clinical benefit, however, a truly placebo-controlled trial will not be possible as the placebo arm would continue lactation and therefore blinding would not be achievable.
To date, bromocriptine may be considered in patients with PPCM (class IIb recommendation). 56 As thromboembolic events have been reported during the use of bromocriptine (albeit mostly at higher dosages), bromocriptine treatment should always be accompanied by anticoagulation at least in prophylactic dosages. Therapies for patients with acute PPCM have been proposed under the BOARD label: Bromocriptine, Oral heart failure therapies, Anticoagulants, vasoRelaxing agents, and Diuretics. 78 If bromocriptine is not available, cabergoline may be used as an alternative to bromocriptine, however apart from two reports 
Prevention of sudden cardiac death and device therapy
Given the high rate of improvement of LV function during optimal heart failure drug therapy, early implantation of an implantable cardioverter-defibrillator (ICD) in patients with newly diagnosed PPCM is generally not advisable. Wearable cardioverter-defibrillators (WCDs) have been proposed as a mechanism to prevent sudden cardiac death during the first 3-6 months after diagnosis until a definitive decision about ICD implantation can be made. 4, 41, 80, 81 In a German registry of patients with severe PPCM, several appropriate shocks were delivered for ventricular fibrillation within the first months. 41, 80 No randomized trials of WCDs in PPCM have yet been started. Although in non-ischaemic cardiomyopathy the necessity of ICD has been questioned in older patients, 82 young patients with severe LV dysfunction despite optimal medical therapy may still derive benefit from ICD implantation. 83 Subcutaneous ICDs represent an alternative to transvenous systems, although they neither provide anti-tachycardia pacing nor post-shock pacing, but can be more easily extracted if cardiac function recovers.
Prognosis, counselling, subsequent pregnancies
The HFA of the ESC Study Group on PPCM published in 2018 a practical guidance paper on the long-term prognosis, subsequent pregnancy, contraception and overall management of patients diagnosed with PPCM. 64 Current evidence for long-term outcome is based mostly on retrospective data or on single-centre prospective studies or small registries covering only 6-12 months postpartum with a wide variation in reported mortality rates, ranging from 2% in Germany 11 to 12.6% from 206 patients with PPCM from South Africa. 66 African American women were more likely to worsen after initial diagnosis, had a lower chance to recover despite apparent adequate treatment. 10 Even after full recovery of LVEF, subtle diastolic dysfunction and reduced maximal exercise capacity (peak oxygen uptake) was reported recently in a Danish PPCM cohort compared to women with previous severe pre-eclampsia and previous uncomplicated pregnancies. 84 Residual cardiac impairment was also shown by assessing echocardiographic tissue Doppler imaging and speckle tracking for myocardial strain imaging. 85 Imaging findings that are associated with an unfavourable outcome include LV end-diastolic diameter > 60 mm, severely depressed LV function (< 30%) and right ventricular dysfunction at initial diagnosis. 9, 86 All patients with a previously diagnosed PPCM and their partners should receive careful counselling (class I recommendation) about the longer-term prognosis and undergo a risk stratification if further pregnancies are considered (see Figure 1 in ref. 64 ). Based on a recent publication reporting on the outcome of women with PPCM and a subsequent pregnancy in cohorts from Germany, Scotland and South Africa, 76, 87 women with an impaired systolic function are at substantial risk of relapse and death, and should therefore be strongly advised against pregnancy. As any subsequent pregnancy in a woman with PPCM entails a substantial risk, those women should be monitored by an experienced multi-disciplinary team throughout pregnancy and for at least 1 year postpartum.
Supplementary Information
Additional supporting information may be found online in the Supporting Information section at the end of the article. Table S1 . Summary of national and international guidance and guideline recommendations on the safety of breastfeeding and heart failure drug therapy. Appendix S1. References of Table 3 .
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